

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 July 2023 (06.07.2023)



(10) International Publication Number
WO 2023/126437 A1

(51) International Patent Classification:

A61K 31/4709 (2006.01) A61P 11/08 (2006.01)
A61K 9/00 (2006.01)

(21) International Application Number:

PCT/EP2022/087954

(22) International Filing Date:

28 December 2022 (28.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21218165.5 29 December 2021 (29.12.2021) EP

(71) Applicants: BAYER AKTIENGESELLSCHAFT

[DE/DE]; Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE). BAYER PHARMA AKTIENGESELLSCHAFT [DE/DE]; Müllerstr. 178, 13353 Berlin (DE).

(72) Inventors: BECKER-PELSTER, Eva, Maria; Düsseldorf

Höhe 22, 42327 Wuppertal (DE). TINEL, Hanna; In der Beek 16, 42113 Wuppertal (DE). HAHN, Michael; Riethebach 42D, 40764 Langenfeld (DE). LANG, Dieter; Wimmersberger Str. 60, 42553 Velbert (DE). WEIMANN, Gerrit; Sattlerweg 12, 51429 Bergisch Gladbach (DE). NAGELSCHMITZ, Johannes; Zum Grossen Busch 58, 42327 Wuppertal (DE). DIETZ, Lisa; An der Grenze 17, 42111 Wuppertal (DE). SALEH, Soundos; Am Jagdhaus 93, 42113 Wuppertal (DE). JUNG, David; Königsholz 62, 58453 Witten (DE). TEREBESI, Ildiko; Reichensteiner Weg 5, 14195 Berlin (DE). MUNDY, Tobias; Rosenheimer Str. 29, 10781 Berlin (DE). RICHTER, Annett;

Goyastr. 8A, 13086 Berlin (DE). OLENIK, Britta; Ludgerstr. 22, 46242 Bottrop (DE). KEIL, Birgit; Sudetenstr. 36, 40231 Düsseldorf (DE). RÖSLER, Bernd; Anilinstr. 8, 42115 Wuppertal (DE). FEY, Peter; Am Eickhof 23, 42111 Wuppertal (DE). SCHIRMER, Heiko; Dingshauser Str. 51a, 42655 Solingen (DE). BECKER, Guido; Bodelschwingstr. 20, 47800 Krefeld (DE). BOTHE, Clemens; Richard-Wagner-Str. 24, 51375 Leverkusen (DE). FABER, Helene; Kollwitzstr. 77, 41539 Dormagen (DE). EGGER, Julian; Anton-Küppers-Weg 15, 42855 Remscheid (DE). PARRY, Mark; 59 Rylstone Way, Saffron Walden, Essex CB11 3BL (GB). WARD, David; 5 The Valley, Comberton, Cambridgeshire CB23 7DF (GB). VITRE, Cecile; 31 Sheralds Croft Lane, Thriplow, Cambridgeshire SG8 7RB (GB).

(74) Agent: BIP PATENTS; c/o Bayer Intellectual Property GmbH, Alfred-Nobel-Straße 50, 40789 Monheim am Rhein (DE).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: TREATMENT OF CARDIOPULMONARY DISORDERS

(57) Abstract: The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), preferably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (II) of formula (I-M-II), in the inhalative treatment of cardiopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension with idiopathic interstitial pneumonia (PH-IIP), characterized in that an inhalative dosage form comprising 240 to 4000 µg, preferably 480 to 2000 µg of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), preferably in form of one of its salts or solvates or hydrates, preferably in form of monohydrate I of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (II) of formula (I-M-II), is administered to a patient in need thereof once or twice daily for a period of at least two consecutive days, preferably at least 2 to 7 consecutive days, preferably for a period of at least 14 consecutive days, in particular from after onset of treatment for the whole course of the disease, wherein the inhalative dosage form preferably comprises the combination of the active ingredient and a pharmaceutically suitable excipient or carrier, while preferably the active ingredient and a pharmaceutically suitable excipient are filled in a hard capsule.

WO 2023/126437 A1

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*